TPD & Induced Proximity Summit Leaderboard
  • Saturday, June 20, 2026
  • About
  • Advertise
  • Subscribe
  • Contact

Pharma Journalist Pharma Journalist -

Oligonucleotides Analytical Development & CMC Summit Leaderboard
  • Home
  • News
  • Drug Research
  • Clinical Trials
  • Manufacturing
  • Information Technology
  • Packaging & Labeling
  • Diseases
  • Resources
    • Articles
    • Projects
    • Case Studies
    • Industry Reports
    • Interviews
    • White Papers
  • Events
  • Press Releases
Pharma Journalist
  • Home
  • Pharma Journalist
  • Page 15

Author

Pharma Journalist 8887 posts 0 comments

Interna, Daiichi Sankyo Partner to Advance Drug Delivery Innovation

Apr 17, 2026
Interna Therapeutics has entered into a new research collaboration with Daiichi Sankyo to explore next-generation approaches to intracellular drug delivery, marking another step forward…
Read More...

Nucleai and Sirona Dx Partner on Spatial Proteomics

Apr 17, 2026
Nucleai and Sirona Dx have announced a strategic partnership aimed at delivering a fully integrated spatial proteomics solution to pharmaceutical and biotechnology companies. The…
Read More...

Terremoto Raises $108M to Advance Targeted Cancer Therapies

Apr 17, 2026
Terremoto Biosciences has secured $108 million in a Series C financing round, strengthening its position in the race to develop next-generation targeted therapies for cancer and rare…
Read More...

Aligos Licenses HBV Drug Candidate to Amoytop in China

Apr 17, 2026
Aligos Therapeutics has entered into an exclusive licensing agreement with Xiamen Amoytop Biotech Co., Ltd. to develop and commercialize its investigational hepatitis B treatment,…
Read More...

Boehringer, Zai Lab Test Dual DLL3 Cancer Therapy

Apr 16, 2026
Boehringer Ingelheim and Zai Lab have announced a new clinical collaboration aimed at advancing a novel dual-targeting strategy for difficult-to-treat cancers. The partnership will…
Read More...

Sana, Mayo Clinic Partner on Diabetes Cell Therapy Development

Apr 15, 2026
Sana Biotechnology has announced a strategic collaboration with Mayo Clinic to accelerate the development of SC451, an investigational cell therapy aimed at transforming treatment for…
Read More...

Lilly to Acquire CrossBridge Bio in $300M Deal

Apr 15, 2026
CrossBridge Bio, Inc., a pre-clinical biotech firm specializing in next-generation antibody-drug conjugates (ADCs), has agreed to be acquired by Eli Lilly and Company in a deal valued…
Read More...

IQ MPS Leaders to Share Industry Progress on Advancing In Vitro NAMs Toward Regulatory Acceptance at…

Apr 14, 2026
As New Approach Methodologies (NAMs) and microphysiological systems (MPS) continue to gain momentum across drug development, the imperative facing industry scientists is increasingly…
Read More...

FDA Rejects Replimune Melanoma Therapy, Citing Data Concerns

Apr 14, 2026
Replimune Group has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration for its Biologics License Application (BLA) seeking approval of RP1 in…
Read More...

Telix and Regeneron Partner on Next-Generation Cancer Therapies

Apr 14, 2026
Telix Pharmaceuticals and Regeneron Pharmaceuticals have announced a strategic collaboration to jointly develop and commercialize next-generation radiopharmaceutical therapies, marking…
Read More...
Prev Next
mRNA Process Development & CMC Summit 2026
TPD & Induced Proximity Summit
Measuring Patient Engagement Summit Europe
Oligonucleotides Analytical Development & CMC Summit
11th CAR-TCR Summit
COPD Drug Development Summit
2nd Operationalize: Expanded Access Programs Summit West
Neuropsychiatric Drug Development Summit
International Neoantigen Summit
Lab Ops & Facility Management for Biopharma West Summit
10th IPF Summit
Medical Device Software Development Summit
Liquid Biopsy for Precision Oncology Summit East Coast
ADC Linker & Conjugation Summit
7th Genome Editing Therapeutics Summit
16th World Clinical Biomarkers & Companion Diagnostics Summit
Lipid Nanoparticles Development Summit Europe
iPSC Drug Development Summit
17th World ADC San Diego
Oligonucleotides for CNS Summit
In Vivo Cell Engineering & Gene Editing Summit
Obesity & Weight Loss Drug Development Summit
T-Cell Engager Therapeutics Summit
mRNA-Based Therapeutics Summit
About Us

Pharma Journalist

Pharma Journalist is a product of Kellen Media. Pharma Journalist is one of the leading website covering the need of global Pharmaceutical Industry.

Articles like latest news, trends, analysis, market report, press releases, whitepapers, case studies, etc. published on pharmajournalist.com helps Industry professionals and decision makers to stay on the top of this fast-paced industry.

Pharma Journalist aims of providing fast and informative articles to its readers and subscribers.

Recent Posts
  • Voro and Alloy Partner on Safer Cancer Immunotherapies
  • uniQure Reports Early Promise for Epilepsy Gene Therapy
  • Boltz and Takeda Expand AI-Powered Drug Discovery Efforts
  • SK Pharmteco Partners With OTXL for Rare Disease Therapies
  • Next-Generation GLP-1 Therapies Are Reshaping the Future of Obesity Treatment

Industry Reports

Amgen Acquires Dark Blue to Advance Novel AML Treatments

Takeda Expands Entyvio Options Through Halozyme Technology…

Inductive Bio Wins $21M to Build AI Drug Toxicity Models

Alkermes Boosts Offer to Acquire Avadel in Deal Worth Up to…

Novartis Completes Acquisition of Tourmaline Bio to…

Press Releases

Advancing Respiratory Medicine Following ATS – What Now?

World ADC San Diego Unveils Preliminary Agenda for 17th…

Regeneron Goes All In on Radiopharma with $2.1B Telix Deal…

IQ MPS Leaders to Share Industry Progress on Advancing In…

4th ADC Linker & Conjugation Summit Announces 2026…

  • About
  • Advertise
  • Subscribe
  • Contact
© 2026 - Pharma Journalist. All Rights Reserved.
Pharma Journalist is a product of
Sign in

Welcome, Login to your account.

Forget password?
Sign in

Recover your password.

A password will be e-mailed to you.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.